Skip to main content
Evidence Snapshot

Insulin receptor

CHEMBL1981 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1981
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Insulin receptor as ChEMBL target CHEMBL1981, mapped to UniProt P06213. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Insulin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1981
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P06213
Insulin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Insulin receptor matters

As of 2026-09-13

Insulin receptor is reviewed as Insulin receptor (UniProt P06213); Insulin receptor shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.; 20 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 4063 compounds, and 940 assays, with lead potency reaching pChEMBL 10.7.

Disease context
diabetes mellitus

Insulin receptor shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 20 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include INSULIN ASPART, INSULIN DEGLUDEC, INSULIN DETEMIR.

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include INSULIN ASPART, INSULIN DEGLUDEC, INSULIN DETEMIR, INSULIN GLARGINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 20 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 4063 compounds, and 940 assays for this target. The dominant activity type is IC50. CHEMBL4226003 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL4226003 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Insulin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P06213, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4063
Total Compounds
940
Total Assays
16
Approved Drugs
IC50: 1851.0, KI: 767.0, EC50: 32.0, KD: 396.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4226003
 10.7 Kd —
No preferred name
CHEMBL514873
 9.4 IC50 —
No preferred name
CHEMBL515519
 9.1 IC50 —
No preferred name
CHEMBL3824326
 9.1 IC50 —
No preferred name
CHEMBL5182271
 9.0 IC50 —

Approved Drugs

Structure Compound First Approval
ENTRECTINIB
CHEMBL1983268
 2019
FEDRATINIB
CHEMBL1287853
 2019
BRIGATINIB
CHEMBL3545311
 2017
OSIMERTINIB
CHEMBL3353410
 2015
CERITINIB
CHEMBL2403108
 2014
NINTEDANIB
CHEMBL502835
 2014
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1981